Authors: Atoui A, Jarrah K, Al Mahmassani L, Bou-Fakhredin R, Taher AT PMID: 35083524 PMCID: PMC8791702 doi: 10.1007/s00277-021-04743-1 Abstract Severe side effects of adenoviral-vectored-DNA COVID-19 vaccines such as thrombosis have been reported. Herein, we report a case of sudden massive deep vein thrombosis (DVT) in a young man with inferior vena cava anomaly 20 hours [...]

Authors: Hasan ZT, AlAtrakji MQ, Mehuaiden AK PMID: 34653660 PMCID: PMC8506572 DOI: 10.1016/j.ijid.2021.10.012 Abstract Objectives: This study aimed to determine the effect of melatonin on thrombosis, sepsis, and mortality rate in adult patients with severe coronavirus infection (COVID-19). Methods: This single-center, prospective, randomized clinical trial was conducted from 1 December 2020 to 1 June 2021 [...]

This study aimed to determine the effect of melatonin on thrombosis, sepsis, and mortality rate in adult patients with severe coronavirus infection (COVID-19).

Authors: Abu-Farha M, Al-Sabah S, Hammad MM, Hebbar P, John SE, Taher I et al. PMID: 33362545 PMCID: PMC7756688 DOI: 10.3389/fphar.2020.587451 Abstract COVID-19 is caused by Severe Acute Respiratory Syndrome Coronavirus-2, which has infected over thirty eight million individuals worldwide. Emerging evidence indicates that COVID-19 patients are at a high risk of developing coagulopathy and [...]

Authors: Barrett TJ, Lee AH, Xia Y, Lin LH, Black M, Cotzia P PMID: 32757722 PMCID: PMC7478197 DOI: 10.1161/CIRCRESAHA.120.317803 Abstract The SARS-CoV-2 (SARS-CoV-2 severe acute respiratory syndrome coronavirus 2) coronavirus disease (COVID-19) is a global pandemic. Laboratory testing suggests a coagulopathy with up to 30% of hospitalized patients with COVID-19 developing thrombotic events.1 Platelets are [...]

Authors: Ackermann M, Verleden SE, Kuehnel M, Haverich A, Welte T PMID: 32437596 PMCID: PMC7412750 DOI: 10.1056/NEJMoa2015432 Abstract Background: Progressive respiratory failure is the primary cause of death in the coronavirus disease 2019 (Covid-19) pandemic. Despite widespread interest in the pathophysiology of the disease, relatively little is known about the associated [...]

Authors: Leisman DE, Deutschman CS, Legrand M PMID: 32347323 PMCID: PMC7186535 DOI: 10.1007/s00134-020-06059-6 Abstract Current management guidelines for COVID-19 reflect the assumption that critically ill patients infected with SARS-CoV-2 develop acute respiratory distress syndrome (ARDS). However, emerging data and clinical reports increasingly suggest an alternative view that severe COVID-19 reflects a confluence of vascular dysfunction, [...]

Authors: Beckman JA PMID: 30560579 PMCID: PMC6516871 doi: 10.1002/14651858.CD004437.pub5 AbstractBackgroundThrombolytic therapy is usually reserved for patients with clinically serious or massive pulmonary embolism (PE). Evidence suggests that thrombolytic agents may dissolve blood clots more rapidly than heparin and may reduce the death rate associated with PE. However, there are still concerns about the possible risk [...]

Authors: Keihanian F, Saeidinia A, Bagheri RK, Johnston TP, Sahebkar A PMID: 29052850 DOI: 10.1002/jcp.26249 Abstract Atherothrombotic cardiovascular disease is a major cause of mortality throughout the world. Platelet activation and aggregation play a central role in hemostasis and thrombosis. Herbal medicines have been traditionally used in the management of cardiovascular disease and can help [...]